Daré Bioscience, Inc. Secures U.S. Patent Extending DARE-HPV Protection to 2039

Daré Bioscience announced a new U.S. patent covering topical lopinavir/ritonavir for HPV-related cervical pathologies, expected to protect DARE-HPV into at least 2039. The Phase 2 study is underway with topline results expected in 2027.Material DetailsContext by AI AnalystThis is an early-to-mid st…